StockFin.ai Try Free →

Sakar Healthcare Limited (SAKAR)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 16 June 2026

₹844.15 ↑ 164.75% (1Y)

🎯 Key Takeaways

Sakar Healthcare Limited is transitioning from a niche domestic player to a growth-oriented specialty pharma with a strategic focus on oncology exports, as evidenced by accelerating revenue and margin trends. The company is in a high-growth phase, leveraging international regulatory approvals and expanding its oncology portfolio to drive future profitability.
Revenue grew 1.5% QoQ to ₹43 in Q3FY25.
⚠️ Overreliance on oncology exports for future growth, which are still in early international markets and subject to regulatory and commercial uncertaint

Market Cap

₹1,550

P/E Ratio

102.3

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About SAKAR 📊 Interactive Charts

📖 The Story

Sakar Healthcare Limited is transitioning from a niche domestic player to a growth-oriented specialty pharma with a strategic focus on oncology exports, as evidenced by accelerating revenue and margin trends. The company is in a high-growth phase, leveraging international regulatory approvals and expanding its oncology portfolio to drive future profitability. Management is actively building a scalable export infrastructure, with clear targets for revenue and oncology contribution by FY27.

📰 What's Happening

In Q4FY26, Sakar Healthcare reported consolidated revenue of ₹7,110 lakhs, up 42% YoY, driven by oncology exports which now contribute 38% of total revenue, up from 21% in FY25. EBITDA grew 67% YoY to ₹2,624 lakhs, and PAT margin improved to 16%. Management highlighted 12 new marketing authorizations for oncology products and ongoing technology transfers with global partners as key catalysts. The company reaffirmed its FY27 revenue target of ~INR380 crores (~40% growth) and projected oncology exports to reach INR50-100 crores over two years, with a long-term goal of INR500 crores total revenue and oncology contributing 60% of sales. These disclosures were made in filings dated May 13, 2026, and May 22, 2026, with no material risks or forward guidance beyond these targets.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	41	39	34	37	43	41	43	43
Operating Profit	10	11	10	9	12	11	12	12
OPM %	19.1%	23.2%	27.5%	24.2%	25.5%	26.0%	26.9%	27.1%
Net Profit	4	3	4	2	3	2	5	5
EPS	₹2.04	₹1.46	₹1.68	₹0.98	₹1.46	₹1.10	₹2.17	₹2.08

The company has demonstrated consistent top-line and bottom-line growth over the past four quarters, with revenue rising from ₹34 crores in Q2FY24 to ₹7,110 lakhs in Q4FY26, and PAT increasing from ₹4 crores to ₹1,102.43 crores annually. Operating margins have stabilized around 25-27% before the recent acceleration to 37% EBITDA margin in Q4FY26, reflecting improved cost efficiency and scale. The sharp rise in oncology exports — from INR22 lakhs to INR30 lakhs YoY — and their growing share of revenue (38%) underscore a structural shift in the business model. This growth trajectory aligns directly with management’s stated focus on expanding international footprint and high-margin oncology products, signaling that recent performance is not episodic but part of a deliberate scaling strategy.

🔮 Management Outlook & What's Next

Management has provided clear forward-looking targets, projecting FY27 revenue of approximately INR380 crores, representing ~40% growth, with oncology exports expected to generate INR50-100 crores over two years and contribute 60% of total revenue in the long term. They also anticipate capacity utilization rising to 50-55% and gross margins improving through the expansion of oncology-based manufacturing and exports. These targets were reiterated in the Q4FY26 results filing on May 13, 2026, and further detailed in the May 22, 2026, financial results commentary. No formal long-term guidance beyond these milestones was disclosed, but the roadmap is explicit in its phased approach to export-led growth.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Overreliance on oncology exports for future growth, which are still in early international markets and subject to regulatory and commercial uncertainty. 2. Margin improvement depends on scaling capacity and technology transfers, which may face execution delays or cost overruns. 3. The company’s growth narrative is heavily tied to international expansion, exposing it to geopolitical, currency, and regulatory risks in export markets. 4. Auditor change in May 2026 (resignation of secretarial auditors) may raise temporary governance concerns, though no operational impact is evident.

📋 Recent Filings

🧠 Analyst's Read

Sakar Healthcare is executing a clear, export-driven growth strategy with early signs of success in oncology, supported by strong quarterly performance and defined FY27 targets. The key watchpoint will be the pace of oncology export ramp-up and realization of margin expansion through scale. Investors should monitor upcoming regulatory approvals and capacity utilization trends to assess progress toward stated milestones.

Based on filing content and financial data. Not a recommendation.

✨ Deep Dive with AI on SAKAR

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-06-16.